{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:40:45Z","timestamp":1794256845410,"version":"4.9.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1097\/md.0000000000008280","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T22:01:19Z","timestamp":1509573679000},"page":"e8280","source":"Crossref","is-referenced-by-count":28,"title":["Efficacy and safety of bevacizumab treatment for refractory brain edema"],"prefix":"10.1097","volume":"96","author":[{"given":"Xiangying","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rugang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapeng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210226","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2214\/AJR.13.11186","article-title":"Gradient of apparent diffusion coefficient values in peritumoral edema helps in differentiation of glioblastoma from solitary metastatic lesions","volume":"203","author":"Lemercier","year":"2014","journal-title":"AJR Am J Roentgenol"},{"key":"R2-8-20210226","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ijrobp.2006.10.010","article-title":"Effect of bevacizumab on radiation necrosis of the brain","volume":"67","author":"Gonzalez","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R3-8-20210226","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/pbc.26055","article-title":"Severe radiation necrosis successfully treated with bevacizumab in an infant with low-grade glioma and tumor-associated intractable trigeminal neuralgia","volume":"63","author":"Pillay Smiley","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"R4-8-20210226","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13014-015-0446-0","article-title":"Intratumoral and peritumoral post-irradiation changes, but not viable tumor tissue, may respond to bevacizumab in previously irradiated meningiomas","volume":"10","author":"Furuse","year":"2015","journal-title":"Radiat Oncol"},{"key":"R5-8-20210226","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/COC.0b013e31829c3139","article-title":"Treatment of cerebral radiation necrosis with bevacizumab: the Cleveland clinic experience","volume":"38","author":"Sadraei","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"R6-8-20210226","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s007010050106","article-title":"Angiogenesis and brain oedema in intracranial meningiomas: influence of vascular endothelial growth factor","volume":"140","author":"Bitzer","year":"1998","journal-title":"Acta Neurochir (Wien"},{"key":"R7-8-20210226","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11060-010-0333-3","article-title":"Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases","volume":"102","author":"Furuse","year":"2011","journal-title":"J Neurooncol"},{"key":"R8-8-20210226","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00415-010-5747-5","article-title":"Favorable outcome with bevacizumab after poor outcome with steroids in a patient with temporal lobe and brainstem radiation necrosis","volume":"258","author":"Benoit","year":"2011","journal-title":"J Neurol"},{"key":"R9-8-20210226","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3171\/2012.1.JNS111627","article-title":"Bevacizumab used for the treatment of severe, refractory perilesional edema due to an arteriovenous malformation treated with stereotactic radiosurgery","volume":"116","author":"Williams","year":"2012","journal-title":"J Neurosurg"},{"key":"R10-8-20210226","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000360930","article-title":"Alleviation of brain edema and restoration of functional independence by bevacizumab in brain-metastatic breast cancer: a case report","volume":"9","author":"Berghoff","year":"2014","journal-title":"Breast Care (Basel"},{"key":"R11-8-20210226","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11060-014-1488-0","article-title":"A new strategy of CyberKnife treatment system based radiosurgery followed by early use of adjuvant bevacizumab treatment for brain metastasis with extensive cerebral edema","volume":"119","author":"Wang","year":"2014","journal-title":"J Neurooncol"},{"key":"R12-8-20210226","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.critrevonc.2015.01.012","article-title":"Bevacizumab: a dose review","volume":"94","author":"Falk","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"R13-8-20210226","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.4103\/0366-6999.161403","article-title":"Relief effect of bevacizumab on severe edema induced by re-irradiation in brain tumor patients","volume":"128","author":"Shen","year":"2015","journal-title":"Chin Med J (Engl"},{"key":"R14-8-20210226","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000376605","article-title":"Bevacizumab-based therapy for patients with brain metastases from non-small-cell lung cancer: preliminary results","volume":"60","author":"Zustovich","year":"2014","journal-title":"Chemotherapy"},{"key":"R15-8-20210226","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","article-title":"Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"R16-8-20210226","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5045\/br.2014.49.3.192","article-title":"Hereditary hemorrhagic telangiectasia treated with low dose intravenous bevacizumab","volume":"49","author":"Wee","year":"2014","journal-title":"Blood Res"},{"key":"R17-8-20210226","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/annonc\/mdr148","article-title":"Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience","volume":"23","author":"Khasraw","year":"2012","journal-title":"Ann Oncol"},{"key":"R18-8-20210226","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cncr.28972","article-title":"Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway","volume":"121","author":"Hamnvik","year":"2015","journal-title":"Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000008280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:36:31Z","timestamp":1620959791000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201711030-00008"}},"subtitle":["Case report"],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":18,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000008280","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}